scholarly journals International Neuroblastoma Staging System

2020 ◽  
Author(s):  
Keyword(s):  
Staging System ◽  
International Neuroblastoma Staging System

International neuroblastoma staging system stage 1 neuroblastoma: a prospective study and literature review.

1996 ◽  
Vol 14 (7) ◽  
pp. 2174-2180 ◽  
Author(s):  
B H Kushner ◽  
N K Cheung ◽  
M P LaQuaglia ◽  
P F Ambros ◽  
I M Ambros ◽  
...  
Keyword(s):  
Prognostic Factors ◽  
Staging System ◽  
Cytotoxic Therapy ◽  
Staging Systems ◽  
International Neuroblastoma Staging System ◽  
A Prospective Study ◽  
Stage 1 ◽  
To Receive ◽  
Insight Into

PURPOSE To gain insight into the management of non-metastatic neuroblastoma by examining clinical and biologic features of International Neuroblastoma Staging System (INSS) stage 1 tumors. METHODS Patients were staged by both the INSS and the Evans staging system and were evaluated for biologic prognostic factors. Patients with INSS stage 1 received no cytotoxic therapy. The literature was reviewed for clinical and biologic data about INSS stage 1. RESULTS We evaluated 10 consecutive patients (median age, 17.5 months) with INSS stage 1; all remain disease-free (median follow-up duration, > 5 years). Tumors were in the abdomen (n = 6), chest (n = 3), or pelvis (n = 1). Neuroblastoma involved margins of resection in six tumors. Poor-prognostic biologic findings included tumor-cell diploidy (n = 2) and unfavorable Shimada histopathology (n = 2). Two patients were to receive chemotherapy for, respectively, a tumor deemed unresectable and a tumor classified as Evans stage III; second opinions resulted in surgical management alone in each case. Published reports confirm that some INSS stage 1 patients (1) are at risk for overtreatment, and (2) have poor-prognostic biologic findings yet do well. CONCLUSION Surgery alone suffices for INSS stage 1 neuroblastoma, even if biologic prognostic factors are unfavorable, microscopic disease remains after surgery, and tumor size is suggestive of "advanced-stage" status in other staging systems. Attempts to resect regionally confined neuroblastomas should take precedence over immediate use of cytotoxic therapy; otherwise, some patients may receive chemotherapy or radiotherapy unnecessarily.

Neuroblastoma na Criança: Relato de Caso/Neuroblastoma in Children: Case Report

1970 ◽  
Vol 3 (1) ◽  
pp. 44-57
Author(s):  
Maysa Carla Mendonça Tame ◽  
Evaldo De Oliveira
Keyword(s):  
Bone Marrow ◽  
Case Report ◽  
Autologous Bone Marrow Transplantation ◽  
Malignant Neoplasm ◽  
Autologous Bone Marrow ◽  
Staging System ◽  
Genetic Alterations ◽  
Autologous Bone ◽  
International Neuroblastoma Staging System ◽  
Systemic Symptoms

 Introdução: o neuroblastoma é uma neoplasia maligna, que apresenta ampla variedade em termos de localização, característica histopatológica e biológica. A apresentação clínica, extremamente variável, reflete as possíveis localizações do tumor primário dentro do sistema nervoso simpático. Os sintomas mais frequentes incluem, dor e distensão abdominais, dores ósseas localizadas, sintomas sistêmicos (anorexia, mal-estar geral, febre) e diarreia. É um tumor raro, com uma incidência de 10 casos por milhão de crianças entre zero e quatro anos de idade. Casuística: Relatou-se o caso de um paciente, atualmente com quatro anos e oito meses, com neuroblastoma, tumor primário de supra-adrenal esquerda, metastático para medula óssea bilateral e múltiplos ossos, que iniciou tratamento quimioterápico-neoadjuvante, imediatamente após o diagnóstico, com posterior avaliação para cirurgia, quimioterapia adjuvante e radioterapia, e transplante autólogo de medula óssea. O tratamento se baseia na estratificação do grupo de risco, podendo envolver: quimioterapia, radioterapia, cirurgia para ressecção do tumor e transplante autólogo de medula óssea. O prognóstico está relacionado com a idade da criança ao diagnóstico, determinadas características histológicas, estadiamento e com alterações genéticas do tumor. Discussão: Seguindo o protocolo, o tumor foi estadiado em nível 4, segundo o International Neuroblastoma Staging System (INSS), e proposto o tratamento com multimodalidade, que inclui quimioterapia intensiva com uma combinação de agentes, seguida de ressecção cirúrgica, doses elevadas de quimioterapia, e radioterapia para posterior transplante autólogo de medula óssea. Este tratamento foi iniciado pela paciente no dia 24/08/2011, e tem previsão de duração de no mínimo um ano. Palavras chave: Neuroblastoma, dores ósseas, glândula adrenal.ABSTRACTIntroduction: Neuroblastoma is a malignant neoplasm that presents a wide variety in terms of location, histopathological and biological characteristic feature. The clinical presentation is extremely variable, reflecting the possible locations of the primary tumor within the sympathetic nervous system. The most common symptoms include abdominal pain and distention, localized bone pain, systemic symptoms (anorexia, malaise, fever), diarrhea. Is a rare tumor, with an incidence of 10 cases per million children between zero and four years old. Case Report: We report the case of a patient, now four years and eight months, with Neuroblastoma, primary adrenal tumor left adrenal, metastatic to bone marrow bilateral and multiple bones, which started neoadjuvant chemotherapy, immediately after diagnosis, with further evaluation for surgery, adjuvant chemotherapy and radiotherapy, and autologous bone marrow. The treatment is based on stratification of risk group and may involve: chemotherapy, radiation, surgery to remove the tumor and autologous bone marrow. The prognosis is related to the child's age at diagnosis, certain histologic features, staging and tumor genetic alterations. Discussion: Following the protocol, the tumor was staged at level 4, according to the International Neuroblastoma Staging System (INSS) and proposed a treatment with multimodality, including an intensive chemotherapy with a combination of agents, followed by surgical resection, high doses of chemotherapy and radiotherapy for subsequent autologous bone marrow transplantation. This treatment was initiated by the patient on 24/08/2011, and is scheduled for a duration of at least one year. Keywords: Neuroblastoma, bone, adrenal gland.

scholarly journals Significance of MYCN Amplification in International Neuroblastoma Staging System Stage 1 and 2 Neuroblastoma: A Report From the International Neuroblastoma Risk Group Database

2009 ◽  
Vol 27 (3) ◽  
pp. 365-370 ◽  
Author(s):  
Rochelle Bagatell ◽  
Maja Beck-Popovic ◽  
Wendy B. London ◽  
Yang Zhang ◽  
Andrew D.J. Pearson ◽  
...  
Keyword(s):  
Risk Group ◽  
Prognostic Significance ◽  
Staging System ◽  
Moderate Intensity ◽  
Mycn Amplification ◽  
Localized Neuroblastoma ◽  
International Neuroblastoma Staging System ◽  
Stage 1 ◽  
Additional Therapy

Purpose Treatment of patients with localized neuroblastoma with unfavorable biologic features is controversial. To evaluate the outcome of children with low-stage MYCN-amplified neuroblastoma and develop a rational treatment strategy, data from the International Neuroblastoma Risk Group (INRG) database were analyzed. Patients and Methods The database is comprised of 8,800 patients. Of these, 2,660 patients (30%) had low-stage (International Neuroblastoma Staging System stages 1 and 2) neuroblastoma, known MYCN status, and available follow-up data. Eighty-seven of these patients (3%) had MYCN amplified tumors. Results Patients with MYCN-amplified, low-stage tumors had less favorable event-free survival (EFS) and overall survival (OS) than did patients with nonamplified tumors (53% ± 8% and 72% ± 7% v 90% ± 1% and 98% ± 1%, respectively). EFS and OS were statistically significantly higher for patients whose tumors were hyperdiploid rather than diploid (EFS, 82% ± 20% v 37% ± 21%; P = .0069; OS, 94% ± 11% v 54% ± 15%; P = .0056, respectively). No other variable had prognostic significance. Initial treatment consisted of surgery alone for 29 (33%) of 87 patients. Details of additional therapy were unknown for 14 patients. Twenty-two patients (25%) underwent surgery and moderate-intensity chemotherapy; another 22 underwent surgery, intensive chemotherapy, and radiation therapy. Nine of the latter 22 underwent stem cell transplantation. Survival in patients who received transplantation did not differ from survival in those who did not receive transplantation. Conclusion Among patients with low-stage, MYCN-amplified neuroblastoma, outcomes of patients with hyperdiploid tumors were statistically, significantly better than those with diploid tumors. The data suggest that tumor cell ploidy could potentially be used to identify candidates for reductions in therapy. Further study of MYCN-amplified, low-stage neuroblastoma is warranted.

scholarly journals Experience with International Neuroblastoma Staging System and Pathology Classification

2002 ◽  
Vol 86 (7) ◽  
pp. 1110-1116 ◽  
Author(s):  
H Ikeda ◽  
T Iehara ◽  
Y Tsuchida ◽  
M Kaneko ◽  
J Hata ◽  
...  
Keyword(s):  
Staging System ◽  
Pathology Classification ◽  
International Neuroblastoma Staging System

New Staging System to Guide Lung Ca Therapy

2009 ◽  
Vol 42 (17) ◽  
pp. 22
Author(s):  
BETSY BATES
Keyword(s):  
Staging System
Sign in / Sign up

Export Citation Format

Share Document